You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Interferon gamma-1b - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for interferon gamma-1b
Recent Clinical Trials for interferon gamma-1b

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of SouthamptonPhase 2
George Washington UniversityPhase 2
University of North Carolina, Chapel HillPhase 2

See all interferon gamma-1b clinical trials

Recent Litigation for interferon gamma-1b

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AMGEN INC. v. APOTEX INC.2022-06-14
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
AMGEN INC. v. EMCURE PHARMACEUTICALS LTD.2018-06-28

See all interferon gamma-1b litigation

Pharmacology for interferon gamma-1b
Established Pharmacologic ClassInterferon gamma
Chemical StructureInterferon-gamma
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for interferon gamma-1b Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for interferon gamma-1b Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for interferon gamma-1b Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Interferon Gamma-1b

Introduction

Interferon gamma-1b, a recombinant human interferon, is a crucial biologic drug used in the treatment of chronic granulomatous disease and severe malignant osteopetrosis. This article delves into the market dynamics and financial trajectory of interferon gamma-1b, highlighting key trends, market size, and future projections.

Market Size and Growth

The global interferons market, which includes interferon gamma-1b, is expected to exhibit significant growth over the coming years. As of 2021, the global interferons market was valued at approximately $9.1 billion and is projected to reach $13.8 billion by 2032, growing at a CAGR of 3.9% from 2022 to 2032[4].

Specific Market for Interferon Gamma-1b

While the overall interferons market provides a broad context, the specific market for interferon gamma-1b is driven by its unique applications. Interferon gamma-1b, marketed under the brand name Actimmune, is primarily used for treating chronic granulomatous disease and severe malignant osteopetrosis. The demand for this drug is influenced by the prevalence of these conditions and the lack of alternative treatments.

Key Trends

Several trends are shaping the market for interferon gamma-1b:

Increasing Prevalence of Target Diseases

The increasing prevalence of chronic granulomatous disease and osteopetrosis, although rare, contributes to the growing demand for interferon gamma-1b. These conditions require specialized treatments, making interferon gamma-1b a critical therapeutic option[2].

Research and Development

Continuous research and development in the field of interferons are expected to boost the market. Innovations in drug delivery and the development of novel interferon beta and gamma formulations are likely to enhance the therapeutic efficacy and patient compliance, thereby driving market growth[1][4].

Regulatory Approvals

Regulatory approvals play a significant role in the market dynamics of biologic drugs. For instance, any new approvals or changes in the regulatory landscape can significantly impact the market size and growth trajectory of interferon gamma-1b.

Financial Performance

Revenue and Sales

The financial performance of interferon gamma-1b is closely tied to the overall sales of the drug. While specific revenue figures for interferon gamma-1b are not readily available, the drug's sales contribute to the broader interferons market revenue. Pharmaceutical companies like those profiled in the interferons market report (e.g., Roche, Merck & Co., Biogen Inc.) invest heavily in research and development, which includes interferon gamma-1b, and these investments are reflected in their overall financial performance[4].

Investment in R&D

Companies are investing significantly in research and development to advance the therapeutic applications of interferon gamma-1b. For example, Amgen's investment in research and development increased by 8% in 2023 to $4.8 billion, indicating a strong commitment to innovative therapies, including biologics like interferon gamma-1b[3].

Regional Market Dynamics

The demand for interferon gamma-1b varies across different regions due to differences in disease prevalence and healthcare infrastructure.

Top Markets

The USA, Germany, the United Kingdom, China, and Japan are among the top countries driving demand for interferons, including interferon gamma-1b. The USA, in particular, accounted for nearly 92.8% of the North American interferons market in 2021[4].

Competitive Landscape

The market for interferon gamma-1b is part of a competitive landscape dominated by several key players in the biopharmaceutical industry. Companies such as Biogen Inc., Merck & Co., and Roche are significant players in the interferons market, and their strategies, including the development of biosimilars and novel formulations, influence the market dynamics[4].

Challenges and Opportunities

Financial Pressure on Healthcare Systems

The high cost of biologic therapies, including interferon gamma-1b, imposes significant financial pressure on healthcare systems globally. This has led to an increased focus on developing biosimilar medications, which could offer more affordable alternatives and drive market growth[4].

Technological Advancements

Advancements in technology and ongoing research are creating opportunities for improving the efficacy and delivery of interferon gamma-1b. For instance, novel delivery routes and formulations can enhance patient compliance and therapeutic outcomes, potentially expanding the market[1][4].

Future Projections

The future of interferon gamma-1b looks promising, driven by several factors:

Growing Demand for Interferons

The increasing prevalence of chronic diseases such as multiple sclerosis, hepatitis, and cancer is expected to drive the demand for interferons, including interferon gamma-1b[4].

Ongoing R&D

Continuous investments in research and development are likely to lead to new therapeutic applications and improved formulations of interferon gamma-1b, further boosting the market.

Regulatory Environment

Favorable regulatory environments and new approvals can significantly impact the market growth of interferon gamma-1b.

Key Takeaways

  • The global interferons market, including interferon gamma-1b, is projected to grow at a CAGR of 3.9% from 2022 to 2032.
  • The increasing prevalence of chronic granulomatous disease and osteopetrosis drives the demand for interferon gamma-1b.
  • Continuous research and development are crucial for the market growth of interferon gamma-1b.
  • The high cost of biologic therapies presents both challenges and opportunities for the development of biosimilars.
  • Regional dynamics, particularly in the USA, Germany, the UK, China, and Japan, play a significant role in the market.

FAQs

What is interferon gamma-1b used for?

Interferon gamma-1b is used for the treatment of chronic granulomatous disease and severe malignant osteopetrosis[2].

How is the global interferons market expected to grow?

The global interferons market is expected to grow at a CAGR of 3.9% from 2022 to 2032, reaching a valuation of $13.8 billion by 2032[4].

Which regions are driving the demand for interferon gamma-1b?

The USA, Germany, the UK, China, and Japan are among the top regions driving demand for interferon gamma-1b[4].

What are the key challenges facing the interferon gamma-1b market?

The high cost of biologic therapies and the financial pressure on healthcare systems are significant challenges. However, these also present opportunities for the development of biosimilars[4].

How is research and development impacting the interferon gamma-1b market?

Continuous investments in research and development are leading to new therapeutic applications and improved formulations, which are expected to boost the market for interferon gamma-1b[1][4].

Sources

  1. Coherent Market Insights - Interferon Beta Drugs Market Size, Trends and Forecast to 2030
  2. DrugBank - Interferon gamma-1b: Uses, Interactions, Mechanism of Action
  3. Amgen Inc. - SHAREHOLDERS 2023
  4. Future Market Insights - Interferons Market Size, Industry Share & Trends - 2032

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.